Korea Investment CORP Trims Stake in United Therapeutics Corporation (UTHR)

Korea Investment CORP trimmed its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 20.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 57,300 shares of the biotechnology company’s stock after selling 14,400 shares during the quarter. Korea Investment CORP owned 0.13% of United Therapeutics Corporation worth $6,715,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Eagle Global Advisors LLC bought a new stake in shares of United Therapeutics Corporation in the second quarter valued at approximately $206,000. TLP Group LLC bought a new stake in shares of United Therapeutics Corporation in the second quarter valued at approximately $246,000. HPM Partners LLC boosted its position in shares of United Therapeutics Corporation by 0.8% in the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after acquiring an additional 15 shares during the period. Fort L.P. boosted its position in shares of United Therapeutics Corporation by 5.2% in the second quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock valued at $261,000 after acquiring an additional 99 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in shares of United Therapeutics Corporation by 4.8% in the first quarter. PNC Financial Services Group Inc. now owns 2,092 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 95 shares during the period.

Several research firms have recently weighed in on UTHR. UBS AG restated a “sell” rating and issued a $106.00 target price on shares of United Therapeutics Corporation in a research note on Thursday, July 6th. ValuEngine upgraded United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research note on Thursday, July 13th. BidaskClub lowered United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Jefferies Group LLC restated a “sell” rating and issued a $105.00 target price on shares of United Therapeutics Corporation in a research note on Friday, July 14th. Finally, Zacks Investment Research lowered United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Five research analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $132.82.

United Therapeutics Corporation (NASDAQ:UTHR) last released its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, beating analysts’ consensus estimates of $4.01 by $2.26. The firm had revenue of $445.50 million during the quarter, compared to the consensus estimate of $426.43 million. United Therapeutics Corporation had a return on equity of 26.24% and a net margin of 30.50%. The company’s revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the company posted $4.23 EPS.

In other news, CEO Martine A. Rothblatt sold 2,176 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $127.11, for a total transaction of $276,591.36. Following the completion of the transaction, the chief executive officer now owns 3,245 shares of the company’s stock, valued at approximately $412,471.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Martine A. Rothblatt sold 1,269 shares of the business’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $118.04, for a total value of $149,792.76. Following the transaction, the chief executive officer now directly owns 1,409 shares of the company’s stock, valued at approximately $166,318.36. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,389 shares of company stock valued at $2,287,452. Corporate insiders own 7.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/11/03/korea-investment-corp-trims-stake-in-united-therapeutics-corporation-uthr.html.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

What are top analysts saying about United Therapeutics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for United Therapeutics Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit